31 results on '"Niemeijer, Anna-Larissa N."'
Number of results to display per page
Search Results
2. Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer.
- Author
-
Muller, Mirte, Best, Myron G., van der Noort, Vincent, Hiltermann, T. Jeroen N., Niemeijer, Anna-Larissa N., Post, Edward, Sol, Nik, In 't Veld, Sjors G.J.G., Nogarede, Tineke, Visser, Lisanne, Schouten, Robert D., van den Broek, Daan, Hummelink, Karlijn, Monkhorst, Kim, de Langen, Adrianus J., Schuuring, Ed, Smit, Egbert F., Groen, Harry J.M., Wurdinger, Thomas, and van den Heuvel, Michel M.
- Subjects
NON-small-cell lung carcinoma ,BLOOD platelets ,NIVOLUMAB ,RNA ,SUPPORT vector machines - Abstract
BACKGROUND: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for immunotherapy. Blood platelets act as active immune-like cells, thereby constraining T-cell activity, propagating cancer metastasis, and adjusting their spliced mRNA content. OBJECTIVE: We investigated whether platelet RNA profiles before start of nivolumab anti-PD1 immunotherapy may predict treatment responses. METHODS: We performed RNA-sequencing of platelet RNA samples isolated from stage III-IV NSCLC patients before treatment with nivolumab. Treatment response was scored by the RECIST-criteria. Data were analyzed using a predefined thromboSeq analysis including a particle-swarm-enhanced support vector machine (PSO/SVM) classification algorithm. RESULTS: We collected and processed a 286-samples cohort, separated into a training/evaluation and validation series and subjected those to training of the PSO/SVM-classification algorithm. We observed only low classification accuracy in the 107-samples validation series (area under the curve (AUC) training series: 0.73 (95% -CI: 0.63–0.84, n = 88 samples), AUC evaluation series: 0.64 (95% -CI: 0.51–0.76, n = 91 samples), AUC validation series: 0.58 (95% -CI: 0.45–0.70, n = 107 samples)), employing a five-RNAs biomarker panel. CONCLUSIONS: We concluded that platelet RNA may have minimally discriminative capacity for anti-PD1 nivolumab response prediction, with which the current methodology is insufficient for diagnostic application. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Supplementary Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
- Author
-
Muller, Mirte, primary, Hummelink, Karlijn, primary, Hurkmans, Daan P., primary, Niemeijer, Anna-Larissa N., primary, Monkhorst, Kim, primary, Roder, Joanna, primary, Oliveira, Carlos, primary, Roder, Heinrich, primary, Aerts, Joachim G., primary, and Smit, Egbert F., primary
- Published
- 2023
- Full Text
- View/download PDF
4. Data from A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
- Author
-
Muller, Mirte, primary, Hummelink, Karlijn, primary, Hurkmans, Daan P., primary, Niemeijer, Anna-Larissa N., primary, Monkhorst, Kim, primary, Roder, Joanna, primary, Oliveira, Carlos, primary, Roder, Heinrich, primary, Aerts, Joachim G., primary, and Smit, Egbert F., primary
- Published
- 2023
- Full Text
- View/download PDF
5. Detection and localization of early- and late-stage cancers using platelet RNA
- Author
-
In ’t Veld, Sjors G.J.G., primary, Arkani, Mohammad, additional, Post, Edward, additional, Antunes-Ferreira, Mafalda, additional, D’Ambrosi, Silvia, additional, Vessies, Daan C.L., additional, Vermunt, Lisa, additional, Vancura, Adrienne, additional, Muller, Mirte, additional, Niemeijer, Anna-Larissa N., additional, Tannous, Jihane, additional, Meijer, Laura L., additional, Le Large, Tessa Y.S., additional, Mantini, Giulia, additional, Wondergem, Niels E., additional, Heinhuis, Kimberley M., additional, van Wilpe, Sandra, additional, Smits, A. Josien, additional, Drees, Esther E.E., additional, Roos, Eva, additional, Leurs, Cyra E., additional, Tjon Kon Fat, Lee-Ann, additional, van der Lelij, Ewoud J., additional, Dwarshuis, Govert, additional, Kamphuis, Maarten J., additional, Visser, Lisanne E., additional, Harting, Romee, additional, Gregory, Annemijn, additional, Schweiger, Markus W., additional, Wedekind, Laurine E., additional, Ramaker, Jip, additional, Zwaan, Kenn, additional, Verschueren, Heleen, additional, Bahce, Idris, additional, de Langen, Adrianus J., additional, Smit, Egbert F., additional, van den Heuvel, Michel M., additional, Hartemink, Koen J., additional, Kuijpers, Marijke J.E., additional, oude Egbrink, Mirjam G.A., additional, Griffioen, Arjan W., additional, Rossel, Rafael, additional, Hiltermann, T. Jeroen N., additional, Lee-Lewandrowski, Elizabeth, additional, Lewandrowski, Kent B., additional, De Witt Hamer, Philip C., additional, Kouwenhoven, Mathilde, additional, Reijneveld, Jaap C., additional, Leenders, William P.J., additional, Hoeben, Ann, additional, Verdonck-de Leeuw, Irma M., additional, Leemans, C. René, additional, Baatenburg de Jong, Robert J., additional, Terhaard, Chris H.J., additional, Takes, Robert P., additional, Langendijk, Johannes A., additional, de Jager, Saskia C., additional, Kraaijeveld, Adriaan O., additional, Pasterkamp, Gerard, additional, Smits, Minke, additional, Schalken, Jack A., additional, Łapińska-Szumczyk, Sylwia, additional, Łojkowska, Anna, additional, Żaczek, Anna J., additional, Lokhorst, Henk, additional, van de Donk, Niels W.C.J., additional, Nijhof, Inger, additional, Prins, Henk-Jan, additional, Zijlstra, Josée M., additional, Idema, Sander, additional, Baayen, Johannes C., additional, Teunissen, Charlotte E., additional, Killestein, Joep, additional, Besselink, Marc G., additional, Brammen, Lindsay, additional, Bachleitner-Hofmann, Thomas, additional, Mateen, Farrah, additional, Plukker, John T.M., additional, Heger, Michal, additional, de Mast, Quirijn, additional, Lisman, Ton, additional, Pegtel, D. Michiel, additional, Bogaard, Harm-Jan, additional, Jassem, Jacek, additional, Supernat, Anna, additional, Mehra, Niven, additional, Gerritsen, Winald, additional, de Kroon, Cornelis D., additional, Lok, Christianne A.R., additional, Piek, Jurgen M.J., additional, Steeghs, Neeltje, additional, van Houdt, Winan J., additional, Brakenhoff, Ruud H., additional, Sonke, Gabe S., additional, Verheul, Henk M., additional, Giovannetti, Elisa, additional, Kazemier, Geert, additional, Sabrkhany, Siamack, additional, Schuuring, Ed, additional, Sistermans, Erik A., additional, Wolthuis, Rob, additional, Meijers-Heijboer, Hanne, additional, Dorsman, Josephine, additional, Oudejans, Cees, additional, Ylstra, Bauke, additional, Westerman, Bart A., additional, van den Broek, Daan, additional, Koppers-Lalic, Danijela, additional, Wesseling, Pieter, additional, Nilsson, R. Jonas A., additional, Vandertop, W. Peter, additional, Noske, David P., additional, Tannous, Bakhos A., additional, Sol, Nik, additional, Best, Myron G., additional, and Wurdinger, Thomas, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Detection and localization of early- and late-stage cancers using platelet RNA
- Author
-
In ’t Veld, Sjors G.J.G., Arkani, Mohammad, Post, Edward, Antunes-Ferreira, Mafalda, D'Ambrosi, Silvia, Vessies, Daan C.L., Vermunt, Lisa, Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Tannous, Jihane, Meijer, Laura L., Le Large, Tessa Y.S., Mantini, Giulia, Wondergem, Niels E., Heinhuis, Kimberley M., van Wilpe, Sandra, Smits, A. Josien, Drees, Esther E.E., Roos, Eva, Leurs, Cyra E., Tjon Kon Fat, Lee Ann, van der Lelij, Ewoud J., Dwarshuis, Govert, Kamphuis, Maarten J., Visser, Lisanne E., Harting, Romee, Gregory, Annemijn, Schweiger, Markus W., Wedekind, Laurine E., Ramaker, Jip, Zwaan, Kenn, Verschueren, Heleen, Bahce, Idris, de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M., Hartemink, Koen J., Kuijpers, Marijke J.E., oude Egbrink, Mirjam G.A., Griffioen, Arjan W., Rossel, Rafael, Hiltermann, T. Jeroen N., Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., De Witt Hamer, Philip C., Kouwenhoven, Mathilde, Reijneveld, Jaap C., Leenders, William P.J., Hoeben, Ann, Verdonck-de Leeuw, Irma M., Leemans, C. René, Baatenburg de Jong, Robert J., Terhaard, Chris H.J., Takes, Robert P., Langendijk, Johannes A., de Jager, Saskia C., Kraaijeveld, Adriaan O., Pasterkamp, Gerard, Smits, Minke, Schalken, Jack A., Łapińska-Szumczyk, Sylwia, Łojkowska, Anna, Żaczek, Anna J., Lokhorst, Henk, van de Donk, Niels W.C.J., Nijhof, Inger, Prins, Henk Jan, Zijlstra, Josée M., Idema, Sander, Baayen, Johannes C., Teunissen, Charlotte E., Killestein, Joep, Besselink, Marc G., Brammen, Lindsay, Bachleitner-Hofmann, Thomas, Mateen, Farrah, Plukker, John T.M., Heger, Michal, de Mast, Quirijn, Lisman, Ton, Pegtel, D. Michiel, Bogaard, Harm Jan, Jassem, Jacek, Supernat, Anna, Mehra, Niven, Gerritsen, Winald, de Kroon, Cornelis D., Lok, Christianne A.R., Piek, Jurgen M.J., Steeghs, Neeltje, van Houdt, Winan J., Brakenhoff, Ruud H., Sonke, Gabe S., Verheul, Henk M., Giovannetti, Elisa, Kazemier, Geert, Sabrkhany, Siamack, Schuuring, Ed, Sistermans, Erik A., Wolthuis, Rob, Meijers-Heijboer, Hanne, Dorsman, Josephine, Oudejans, Cees, Ylstra, Bauke, Westerman, Bart A., van den Broek, Daan, Koppers-Lalic, Danijela, Wesseling, Pieter, Nilsson, R. Jonas A., Vandertop, W. Peter, Noske, David P., Tannous, Bakhos A., Sol, Nik, Best, Myron G., Wurdinger, Thomas, In ’t Veld, Sjors G.J.G., Arkani, Mohammad, Post, Edward, Antunes-Ferreira, Mafalda, D'Ambrosi, Silvia, Vessies, Daan C.L., Vermunt, Lisa, Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Tannous, Jihane, Meijer, Laura L., Le Large, Tessa Y.S., Mantini, Giulia, Wondergem, Niels E., Heinhuis, Kimberley M., van Wilpe, Sandra, Smits, A. Josien, Drees, Esther E.E., Roos, Eva, Leurs, Cyra E., Tjon Kon Fat, Lee Ann, van der Lelij, Ewoud J., Dwarshuis, Govert, Kamphuis, Maarten J., Visser, Lisanne E., Harting, Romee, Gregory, Annemijn, Schweiger, Markus W., Wedekind, Laurine E., Ramaker, Jip, Zwaan, Kenn, Verschueren, Heleen, Bahce, Idris, de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M., Hartemink, Koen J., Kuijpers, Marijke J.E., oude Egbrink, Mirjam G.A., Griffioen, Arjan W., Rossel, Rafael, Hiltermann, T. Jeroen N., Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., De Witt Hamer, Philip C., Kouwenhoven, Mathilde, Reijneveld, Jaap C., Leenders, William P.J., Hoeben, Ann, Verdonck-de Leeuw, Irma M., Leemans, C. René, Baatenburg de Jong, Robert J., Terhaard, Chris H.J., Takes, Robert P., Langendijk, Johannes A., de Jager, Saskia C., Kraaijeveld, Adriaan O., Pasterkamp, Gerard, Smits, Minke, Schalken, Jack A., Łapińska-Szumczyk, Sylwia, Łojkowska, Anna, Żaczek, Anna J., Lokhorst, Henk, van de Donk, Niels W.C.J., Nijhof, Inger, Prins, Henk Jan, Zijlstra, Josée M., Idema, Sander, Baayen, Johannes C., Teunissen, Charlotte E., Killestein, Joep, Besselink, Marc G., Brammen, Lindsay, Bachleitner-Hofmann, Thomas, Mateen, Farrah, Plukker, John T.M., Heger, Michal, de Mast, Quirijn, Lisman, Ton, Pegtel, D. Michiel, Bogaard, Harm Jan, Jassem, Jacek, Supernat, Anna, Mehra, Niven, Gerritsen, Winald, de Kroon, Cornelis D., Lok, Christianne A.R., Piek, Jurgen M.J., Steeghs, Neeltje, van Houdt, Winan J., Brakenhoff, Ruud H., Sonke, Gabe S., Verheul, Henk M., Giovannetti, Elisa, Kazemier, Geert, Sabrkhany, Siamack, Schuuring, Ed, Sistermans, Erik A., Wolthuis, Rob, Meijers-Heijboer, Hanne, Dorsman, Josephine, Oudejans, Cees, Ylstra, Bauke, Westerman, Bart A., van den Broek, Daan, Koppers-Lalic, Danijela, Wesseling, Pieter, Nilsson, R. Jonas A., Vandertop, W. Peter, Noske, David P., Tannous, Bakhos A., Sol, Nik, Best, Myron G., and Wurdinger, Thomas
- Abstract
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I–IV cancer patients and in half of 352 stage I–III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening.
- Published
- 2022
7. Detection and localization of early- and late-stage cancers using platelet RNA
- Author
-
Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Afd Pharmaceutics, In ’t Veld, Sjors G.J.G., Arkani, Mohammad, Post, Edward, Antunes-Ferreira, Mafalda, D'Ambrosi, Silvia, Vessies, Daan C.L., Vermunt, Lisa, Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Tannous, Jihane, Meijer, Laura L., Le Large, Tessa Y.S., Mantini, Giulia, Wondergem, Niels E., Heinhuis, Kimberley M., van Wilpe, Sandra, Smits, A. Josien, Drees, Esther E.E., Roos, Eva, Leurs, Cyra E., Tjon Kon Fat, Lee Ann, van der Lelij, Ewoud J., Dwarshuis, Govert, Kamphuis, Maarten J., Visser, Lisanne E., Harting, Romee, Gregory, Annemijn, Schweiger, Markus W., Wedekind, Laurine E., Ramaker, Jip, Zwaan, Kenn, Verschueren, Heleen, Bahce, Idris, de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M., Hartemink, Koen J., Kuijpers, Marijke J.E., oude Egbrink, Mirjam G.A., Griffioen, Arjan W., Rossel, Rafael, Hiltermann, T. Jeroen N., Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., De Witt Hamer, Philip C., Kouwenhoven, Mathilde, Reijneveld, Jaap C., Leenders, William P.J., Hoeben, Ann, Verdonck-de Leeuw, Irma M., Leemans, C. René, Baatenburg de Jong, Robert J., Terhaard, Chris H.J., Takes, Robert P., Langendijk, Johannes A., de Jager, Saskia C., Kraaijeveld, Adriaan O., Pasterkamp, Gerard, Smits, Minke, Schalken, Jack A., Łapińska-Szumczyk, Sylwia, Łojkowska, Anna, Żaczek, Anna J., Lokhorst, Henk, van de Donk, Niels W.C.J., Nijhof, Inger, Prins, Henk Jan, Zijlstra, Josée M., Idema, Sander, Baayen, Johannes C., Teunissen, Charlotte E., Killestein, Joep, Besselink, Marc G., Brammen, Lindsay, Bachleitner-Hofmann, Thomas, Mateen, Farrah, Plukker, John T.M., Heger, Michal, de Mast, Quirijn, Lisman, Ton, Pegtel, D. Michiel, Bogaard, Harm Jan, Jassem, Jacek, Supernat, Anna, Mehra, Niven, Gerritsen, Winald, de Kroon, Cornelis D., Lok, Christianne A.R., Piek, Jurgen M.J., Steeghs, Neeltje, van Houdt, Winan J., Brakenhoff, Ruud H., Sonke, Gabe S., Verheul, Henk M., Giovannetti, Elisa, Kazemier, Geert, Sabrkhany, Siamack, Schuuring, Ed, Sistermans, Erik A., Wolthuis, Rob, Meijers-Heijboer, Hanne, Dorsman, Josephine, Oudejans, Cees, Ylstra, Bauke, Westerman, Bart A., van den Broek, Daan, Koppers-Lalic, Danijela, Wesseling, Pieter, Nilsson, R. Jonas A., Vandertop, W. Peter, Noske, David P., Tannous, Bakhos A., Sol, Nik, Best, Myron G., Wurdinger, Thomas, Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Afd Pharmaceutics, In ’t Veld, Sjors G.J.G., Arkani, Mohammad, Post, Edward, Antunes-Ferreira, Mafalda, D'Ambrosi, Silvia, Vessies, Daan C.L., Vermunt, Lisa, Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Tannous, Jihane, Meijer, Laura L., Le Large, Tessa Y.S., Mantini, Giulia, Wondergem, Niels E., Heinhuis, Kimberley M., van Wilpe, Sandra, Smits, A. Josien, Drees, Esther E.E., Roos, Eva, Leurs, Cyra E., Tjon Kon Fat, Lee Ann, van der Lelij, Ewoud J., Dwarshuis, Govert, Kamphuis, Maarten J., Visser, Lisanne E., Harting, Romee, Gregory, Annemijn, Schweiger, Markus W., Wedekind, Laurine E., Ramaker, Jip, Zwaan, Kenn, Verschueren, Heleen, Bahce, Idris, de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M., Hartemink, Koen J., Kuijpers, Marijke J.E., oude Egbrink, Mirjam G.A., Griffioen, Arjan W., Rossel, Rafael, Hiltermann, T. Jeroen N., Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., De Witt Hamer, Philip C., Kouwenhoven, Mathilde, Reijneveld, Jaap C., Leenders, William P.J., Hoeben, Ann, Verdonck-de Leeuw, Irma M., Leemans, C. René, Baatenburg de Jong, Robert J., Terhaard, Chris H.J., Takes, Robert P., Langendijk, Johannes A., de Jager, Saskia C., Kraaijeveld, Adriaan O., Pasterkamp, Gerard, Smits, Minke, Schalken, Jack A., Łapińska-Szumczyk, Sylwia, Łojkowska, Anna, Żaczek, Anna J., Lokhorst, Henk, van de Donk, Niels W.C.J., Nijhof, Inger, Prins, Henk Jan, Zijlstra, Josée M., Idema, Sander, Baayen, Johannes C., Teunissen, Charlotte E., Killestein, Joep, Besselink, Marc G., Brammen, Lindsay, Bachleitner-Hofmann, Thomas, Mateen, Farrah, Plukker, John T.M., Heger, Michal, de Mast, Quirijn, Lisman, Ton, Pegtel, D. Michiel, Bogaard, Harm Jan, Jassem, Jacek, Supernat, Anna, Mehra, Niven, Gerritsen, Winald, de Kroon, Cornelis D., Lok, Christianne A.R., Piek, Jurgen M.J., Steeghs, Neeltje, van Houdt, Winan J., Brakenhoff, Ruud H., Sonke, Gabe S., Verheul, Henk M., Giovannetti, Elisa, Kazemier, Geert, Sabrkhany, Siamack, Schuuring, Ed, Sistermans, Erik A., Wolthuis, Rob, Meijers-Heijboer, Hanne, Dorsman, Josephine, Oudejans, Cees, Ylstra, Bauke, Westerman, Bart A., van den Broek, Daan, Koppers-Lalic, Danijela, Wesseling, Pieter, Nilsson, R. Jonas A., Vandertop, W. Peter, Noske, David P., Tannous, Bakhos A., Sol, Nik, Best, Myron G., and Wurdinger, Thomas
- Published
- 2022
8. PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
- Author
-
Smit, Jasper, primary, Borm, Frank Johannes, additional, Niemeijer, Anna-Larissa N, additional, Huisman, Marc C, additional, Hoekstra, Otto S, additional, Boellaard, Ronald, additional, Oprea-Lager, Daniela Elena, additional, Vugts, Danielle J, additional, van Dongen, Guus AMS, additional, de Wit- van der Veen, Berlinda J, additional, Thunnissen, Erik, additional, Smit, Egbert F, additional, and de Langen, Adrianus J, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
- Author
-
Niemeijer, Anna-Larissa N., primary, Oprea-Lager, Daniela E., additional, Huisman, Marc C., additional, Hoekstra, Otto S., additional, Boellaard, Ronald, additional, de Wit-van der Veen, Berlinda J., additional, Bahce, Idris, additional, Vugts, Daniëlle J., additional, van Dongen, Guus A.M.S., additional, Thunnissen, Erik, additional, Smit, Egbert F., additional, and de Langen, Adrianus J., additional
- Published
- 2021
- Full Text
- View/download PDF
10. A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
- Author
-
Muller, Mirte, primary, Hummelink, Karlijn, additional, Hurkmans, Daan P., additional, Niemeijer, Anna-Larissa N., additional, Monkhorst, Kim, additional, Roder, Joanna, additional, Oliveira, Carlos, additional, Roder, Heinrich, additional, Aerts, Joachim G., additional, and Smit, Egbert F., additional
- Published
- 2020
- Full Text
- View/download PDF
11. Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer
- Author
-
Huisman, Marc C., primary, Niemeijer, Anna-Larissa N., additional, Windhorst, Albert D., additional, Schuit, Robert C., additional, Leung, David, additional, Hayes, Wendy, additional, Poot, Alex, additional, Bahce, Idris, additional, Radonic, Teodora, additional, Oprea-Lager, Daniela E., additional, Hoekstra, Otto S., additional, Thunnissen, Erik, additional, Hendrikse, N. Harry, additional, Smit, Egbert F., additional, de Langen, Adrianus J., additional, and Boellaard, Ronald, additional
- Published
- 2020
- Full Text
- View/download PDF
12. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Author
-
Niemeijer, Anna-Larissa N., Oprea-Lager, Daniela E., Huisman, Marc C., Hoekstra, Otto S., Boellaard, Ronald, de Wit-van der Veen, Berlinda J., Bahce, Idris, Vugts, Daniëlle J., van Dongen, Guus AMS, Thunnissen, Erik, Smit, Egbert F., and de Langen, Adrianus J.
- Published
- 2021
- Full Text
- View/download PDF
13. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
- Author
-
Niemeijer, Anna-Larissa N., Oprea-Lager, Daniela E., Huisman, Marc C., Hoekstra, Otto S., Boellaard, Ronald, de Wit-van der Veen, Berlinda J., Bahce, Idris, Vugts, Daniëlle J., van Dongen, Guus A. M. S., Thunnissen, Erik, Smit, Egbert F., and de Langen, Adrianus J.
- Published
- 2021
- Full Text
- View/download PDF
14. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small- cell lung cancer . .
- Author
-
Niemeijer, Anna-Larissa N., Oprea-Lager, Daniela E., Huisman, Marc C., Hoekstra, Otto S, Boellaard, Ronald, de Wit-van der Veen, Berlinda J., Bahce, Idris., Vugts, Daniëlle J., van Dongen, Guus AMS, Thunnissen, Erik, Smit, Egbert F., and de Langen, Adrianus J.
- Published
- 2021
- Full Text
- View/download PDF
15. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
- Author
-
Niemeijer, Anna-Larissa N., Oprea-Lager, Daniela E., Huisman, Marc C., Hoekstra, Otto S., Boellaard, Ronald, de Wit-van der Veen, Berlinda J., Bahce, Idris, Vugts, Daniëlle J., van Dongen, Guus AMS, Thunnissen, Erik, Smit, Egbert F., and de Langen, Adrianus J.
- Published
- 2021
- Full Text
- View/download PDF
16. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- Author
-
Theelen, Willemijn S. M. E., primary, Peulen, Heike M. U., additional, Lalezari, Ferry, additional, van der Noort, Vincent, additional, de Vries, Jeltje F., additional, Aerts, Joachim G. J. V., additional, Dumoulin, Daphne W., additional, Bahce, Idris, additional, Niemeijer, Anna-Larissa N., additional, de Langen, Adrianus J., additional, Monkhorst, Kim, additional, and Baas, Paul, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Radiotherapy Augments Pembrolizumab Responses and Outcomes in Metastatic Non-Small Cell Lung Cancer: Pooled Analysis of Two Randomized Trials
- Author
-
Theelen, Willemijn S. M. E., primary, Chen, Dawei, additional, Baas, Paul, additional, Hobbs, Brian, additional, Fellman, Bryan, additional, Peulen, Heike M. U., additional, Aerts, Joachim G. J. V., additional, Bahce, Idris, additional, Niemeijer, Anna Larissa N., additional, Verma, Vivek, additional, Chang, Joe Y., additional, de Groot, Patricia M., additional, Nguyen, Quynh-Nhu, additional, Comeaux, Nathan I., additional, Simon, George R., additional, Skoulidis, Ferdinandos, additional, Lin, Steven H., additional, Patel, Roshal, additional, Guo, Chunxiao, additional, Heymach, John, additional, and Welsh, James W., additional
- Published
- 2019
- Full Text
- View/download PDF
18. Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Author
-
Huisman, Marc C., Niemeijer, Anna-Larissa N., Windhorst, Albert D., Schuit, Robert C., Leung, David, Hayes, Wendy, Poot, Alex, Bahce, Idris, Radonic, Teodora, Oprea-Lager, Daniela E., Hoekstra, Otto S., Thunnissen, Erik, Hendrikse, Harry, Smit, Egbert F., de Langen, Adrianus J., and Boellaard, Ronald
- Published
- 2020
- Full Text
- View/download PDF
19. Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
- Author
-
Huisman, Marc C., Niemeijer, Anna-Larissa N., Windhorst, Albert D., Schuit, Robert C., Leung, David, Hayes, Wendy, Poot, Alex, Bahce, Idris, Radonic, Teodora, Oprea-Lager, Daniela E., Hoekstra, Otto S., Thunnissen, Erik, Hendrikse, N. Harry, Smit, Egbert F., de Langen, Adrianus J., and Boellaard, Ronald
- Published
- 2020
- Full Text
- View/download PDF
20. Whole body PD-L1 PET in patients with NSCLC and melanoma.
- Author
-
Leung, David K., primary, De Langen, Joop, additional, Raunig, David, additional, Niemeijer, Anna-Larissa N., additional, Smit, Egbert F., additional, Boellaard, Ronald, additional, Vallez-Garcia, David, additional, Dongen, G.a.M.S. van, additional, Windhorst, A.D., additional, Huisman, Marc C., additional, Glaudemans, Andor W. J. M., additional, Hendrikse, N. Harry, additional, Smith, Ralph Adam, additional, Poot, Alex J., additional, Lipovsek, Dasa, additional, Donnelly, David J., additional, Bonacorsi, Samuel J., additional, Velasquez, Linda M., additional, Du, Shuyan, additional, and Hayes, Wendy, additional
- Published
- 2018
- Full Text
- View/download PDF
21. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets
- Author
-
Best, Myron G., Sol, Nik, In ‘t Veld, Sjors G.J.G., Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Fejes, Aniko V., Tjon Kon Fat, Lee Ann, Huis in 't Veld, Anna E, Leurs, Cyra, Le Large, Tessa Y., Meijer, Laura L., Kooi, Irsan E., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Wedekind, Laurine E., Bracht, Jillian, Esenkbrink, Michelle, Wils, Leon, Favaro, Francesca, Schoonhoven, Jilian D., Tannous, Jihane, Meijers-Heijboer, Hanne, Kazemier, Geert, Giovannetti, Elisa, Reijneveld, Jaap C., Idema, Sander, Killestein, Joep, Heger, Michal, de Jager, Saskia C., Urbanus, Rolf T., Hoefer, Imo E., Pasterkamp, Gerard, Mannhalter, Christine, Gomez-Arroyo, Jose, Bogaard, Harm-Jan, Noske, David P., Vandertop, W. Peter, van den Broek, Daan, Ylstra, Bauke, Nilsson, R. Jonas A, Wesseling, Pieter, Karachaliou, Niki, Rosell, Rafael, Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., Tannous, Bakhos A., de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M, Wurdinger, Thomas, Best, Myron G., Sol, Nik, In ‘t Veld, Sjors G.J.G., Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Fejes, Aniko V., Tjon Kon Fat, Lee Ann, Huis in 't Veld, Anna E, Leurs, Cyra, Le Large, Tessa Y., Meijer, Laura L., Kooi, Irsan E., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Wedekind, Laurine E., Bracht, Jillian, Esenkbrink, Michelle, Wils, Leon, Favaro, Francesca, Schoonhoven, Jilian D., Tannous, Jihane, Meijers-Heijboer, Hanne, Kazemier, Geert, Giovannetti, Elisa, Reijneveld, Jaap C., Idema, Sander, Killestein, Joep, Heger, Michal, de Jager, Saskia C., Urbanus, Rolf T., Hoefer, Imo E., Pasterkamp, Gerard, Mannhalter, Christine, Gomez-Arroyo, Jose, Bogaard, Harm-Jan, Noske, David P., Vandertop, W. Peter, van den Broek, Daan, Ylstra, Bauke, Nilsson, R. Jonas A, Wesseling, Pieter, Karachaliou, Niki, Rosell, Rafael, Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., Tannous, Bakhos A., de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M, and Wurdinger, Thomas
- Published
- 2017
22. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets
- Author
-
UMC Utrecht, Experimentele Afd. Cardiologie 2, CDL Staf Research, Circulatory Health, CDL Arcadia, CDL Cluster Onderzoek en Onderwijs, Pathologie Groep Moelans, Pathologie Pathologen staf, Arts Assistenten Longziekten, Arts-assistenten Radiologie, Brain, Best, Myron G., Sol, Nik, In ‘t Veld, Sjors G.J.G., Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Fejes, Aniko V., Tjon Kon Fat, Lee Ann, Huis in 't Veld, Anna E, Leurs, Cyra, Le Large, Tessa Y., Meijer, Laura L., Kooi, Irsan E., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Wedekind, Laurine E., Bracht, Jillian, Esenkbrink, Michelle, Wils, Leon, Favaro, Francesca, Schoonhoven, Jilian D., Tannous, Jihane, Meijers-Heijboer, Hanne, Kazemier, Geert, Giovannetti, Elisa, Reijneveld, Jaap C., Idema, Sander, Killestein, Joep, Heger, Michal, de Jager, Saskia C., Urbanus, Rolf T., Hoefer, Imo E., Pasterkamp, Gerard, Mannhalter, Christine, Gomez-Arroyo, Jose, Bogaard, Harm-Jan, Noske, David P., Vandertop, W. Peter, van den Broek, Daan, Ylstra, Bauke, Nilsson, R. Jonas A, Wesseling, Pieter, Karachaliou, Niki, Rosell, Rafael, Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., Tannous, Bakhos A., de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M, Wurdinger, Thomas, UMC Utrecht, Experimentele Afd. Cardiologie 2, CDL Staf Research, Circulatory Health, CDL Arcadia, CDL Cluster Onderzoek en Onderwijs, Pathologie Groep Moelans, Pathologie Pathologen staf, Arts Assistenten Longziekten, Arts-assistenten Radiologie, Brain, Best, Myron G., Sol, Nik, In ‘t Veld, Sjors G.J.G., Vancura, Adrienne, Muller, Mirte, Niemeijer, Anna Larissa N., Fejes, Aniko V., Tjon Kon Fat, Lee Ann, Huis in 't Veld, Anna E, Leurs, Cyra, Le Large, Tessa Y., Meijer, Laura L., Kooi, Irsan E., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Wedekind, Laurine E., Bracht, Jillian, Esenkbrink, Michelle, Wils, Leon, Favaro, Francesca, Schoonhoven, Jilian D., Tannous, Jihane, Meijers-Heijboer, Hanne, Kazemier, Geert, Giovannetti, Elisa, Reijneveld, Jaap C., Idema, Sander, Killestein, Joep, Heger, Michal, de Jager, Saskia C., Urbanus, Rolf T., Hoefer, Imo E., Pasterkamp, Gerard, Mannhalter, Christine, Gomez-Arroyo, Jose, Bogaard, Harm-Jan, Noske, David P., Vandertop, W. Peter, van den Broek, Daan, Ylstra, Bauke, Nilsson, R. Jonas A, Wesseling, Pieter, Karachaliou, Niki, Rosell, Rafael, Lee-Lewandrowski, Elizabeth, Lewandrowski, Kent B., Tannous, Bakhos A., de Langen, Adrianus J., Smit, Egbert F., van den Heuvel, Michel M, and Wurdinger, Thomas
- Published
- 2017
23. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets
- Author
-
Best, Myron G., primary, Sol, Nik, additional, In ‘t Veld, Sjors G.J.G., additional, Vancura, Adrienne, additional, Muller, Mirte, additional, Niemeijer, Anna-Larissa N., additional, Fejes, Aniko V., additional, Tjon Kon Fat, Lee-Ann, additional, Huis In ‘t Veld, Anna E., additional, Leurs, Cyra, additional, Le Large, Tessa Y., additional, Meijer, Laura L., additional, Kooi, Irsan E., additional, Rustenburg, François, additional, Schellen, Pepijn, additional, Verschueren, Heleen, additional, Post, Edward, additional, Wedekind, Laurine E., additional, Bracht, Jillian, additional, Esenkbrink, Michelle, additional, Wils, Leon, additional, Favaro, Francesca, additional, Schoonhoven, Jilian D., additional, Tannous, Jihane, additional, Meijers-Heijboer, Hanne, additional, Kazemier, Geert, additional, Giovannetti, Elisa, additional, Reijneveld, Jaap C., additional, Idema, Sander, additional, Killestein, Joep, additional, Heger, Michal, additional, de Jager, Saskia C., additional, Urbanus, Rolf T., additional, Hoefer, Imo E., additional, Pasterkamp, Gerard, additional, Mannhalter, Christine, additional, Gomez-Arroyo, Jose, additional, Bogaard, Harm-Jan, additional, Noske, David P., additional, Vandertop, W. Peter, additional, van den Broek, Daan, additional, Ylstra, Bauke, additional, Nilsson, R. Jonas A., additional, Wesseling, Pieter, additional, Karachaliou, Niki, additional, Rosell, Rafael, additional, Lee-Lewandrowski, Elizabeth, additional, Lewandrowski, Kent B., additional, Tannous, Bakhos A., additional, de Langen, Adrianus J., additional, Smit, Egbert F., additional, van den Heuvel, Michel M., additional, and Wurdinger, Thomas, additional
- Published
- 2017
- Full Text
- View/download PDF
24. Abstract LB-248: RNA-sequencing of tumor-educated platelets enables nivolumab immunotherapy response prediction
- Author
-
Muller, Mirte, primary, Best, Myron, additional, Sol, Nik, additional, Niemeijer, Anna-Larissa N., additional, Vancura, Adrienne, additional, Schouten, Robert D., additional, Hiltermann, Jeroen J.N., additional, Veld, Sjors G.J.G. In 't, additional, Broek, Daan van den, additional, Noort, Vincent van der, additional, Langen, Adrianus J. de, additional, Schuuring, Ed M.D., additional, Wurdinger, Thomas, additional, and Heuvel, Michel M. van den, additional
- Published
- 2017
- Full Text
- View/download PDF
25. Abstract 4584: High PD-1 expression on regulatory and effector T cells in lung cancer draining lymph nodes
- Author
-
Ven, Rieneke Van De, primary, Niemeijer, Anna-Larissa N., additional, Stam, Anita G., additional, Hashemi, Sayed M., additional, Slockers, Christian G., additional, Daniels, Johannes M., additional, Thunnissen, Erik, additional, Smit, Egbert F., additional, Gruijl, Tanja D. de, additional, and Langen, Adrianus J. de, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F- BMS-986192 in pts with NSCLC.
- Author
-
Niemeijer, Anna-Larissa N., primary, Smit, Egbert F., additional, Dongen, G.a.M.S. van, additional, Windhorst, A.D., additional, Huisman, Marc C., additional, Hendrikse, N. Harry, additional, Leung, David K., additional, Smith, Ralph Adam, additional, Hayes, Wendy, additional, Velasquez, Linda M., additional, Bonacorsi, Samuel J., additional, Donnelly, David J., additional, Morin, Paul E., additional, Thunnissen, Erik, additional, Poot, Alex J., additional, Vugts, Danielle J., additional, and De Langen, Joop, additional
- Published
- 2017
- Full Text
- View/download PDF
27. High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes
- Author
-
van de Ven, Rieneke, primary, Niemeijer, Anna-Larissa N., additional, Stam, Anita G.M., additional, Hashemi, Sayed M.S., additional, Slockers, Christian G., additional, Daniels, Johannes M., additional, Thunnissen, Erik, additional, Smit, Egbert F., additional, de Gruijl, Tanja D., additional, and de Langen, Adrianus J., additional
- Published
- 2017
- Full Text
- View/download PDF
28. Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer.
- Author
-
Muller M, Best MG, van der Noort V, Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG, Nogarede T, Visser L, Schouten RD, van den Broek D, Hummelink K, Monkhorst K, de Langen AJ, Schuuring E, Smit EF, Groen HJM, Wurdinger T, and van den Heuvel MM
- Subjects
- Humans, Nivolumab therapeutic use, Blood Platelets pathology, RNA genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology
- Abstract
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for immunotherapy. Blood platelets act as active immune-like cells, thereby constraining T-cell activity, propagating cancer metastasis, and adjusting their spliced mRNA content., Objective: We investigated whether platelet RNA profiles before start of nivolumab anti-PD1 immunotherapy may predict treatment responses., Methods: We performed RNA-sequencing of platelet RNA samples isolated from stage III-IV NSCLC patients before treatment with nivolumab. Treatment response was scored by the RECIST-criteria. Data were analyzed using a predefined thromboSeq analysis including a particle-swarm-enhanced support vector machine (PSO/SVM) classification algorithm., Results: We collected and processed a 286-samples cohort, separated into a training/evaluation and validation series and subjected those to training of the PSO/SVM-classification algorithm. We observed only low classification accuracy in the 107-samples validation series (area under the curve (AUC) training series: 0.73 (95% -CI: 0.63-0.84, n = 88 samples), AUC evaluation series: 0.64 (95% -CI: 0.51-0.76, n = 91 samples), AUC validation series: 0.58 (95% -CI: 0.45-0.70, n = 107 samples)), employing a five-RNAs biomarker panel., Conclusions: We concluded that platelet RNA may have minimally discriminative capacity for anti-PD1 nivolumab response prediction, with which the current methodology is insufficient for diagnostic application.
- Published
- 2024
- Full Text
- View/download PDF
29. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
- Author
-
Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, Oprea-Lager DE, Vugts DJ, van Dongen GAMS, de Wit-van der Veen BJ, Thunnissen E, Smit EF, and de Langen AJ
- Subjects
- Antibodies, Monoclonal, B7-H1 Antigen metabolism, Humans, Positron Emission Tomography Computed Tomography, Tissue Distribution, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms diagnostic imaging, Lung Neoplasms drug therapy, Lung Neoplasms pathology
- Abstract
Better biomarkers are needed to predict treatment outcome in non-small cell lung cancer (NSCLC) patients treated with anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint inhibitors. PD-L1 immunohistochemistry has limited predictive value, possibly because of tumor heterogeneity of PD-L1 expression. Noninvasive PD-L1 imaging using
89 Zr-durvalumab might better reflect tumor PD-L1 expression. Methods: NSCLC patients eligible for second-line immunotherapy were enrolled. Patients received 2 injections of89 Zr-durvalumab: one without a preceding dose of unlabeled durvalumab (tracer dose only) and one with a preceding dose of 750 mg of durvalumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 750 mg of durvalumab every 2 wk. Tracer biodistribution and tumor uptake were visually assessed and quantified as SUV, and both imaging acquisitions were compared. Tumor tracer uptake was correlated with PD-L1 expression and clinical outcome, defined as response to durvalumab treatment. Results: Thirteen patients were included, and 10 completed all scheduled PET scans. No tracer-related adverse events were observed, and all patients started durvalumab treatment. Biodistribution analysis showed89 Zr-durvalumab accumulation in the blood pool, liver, and spleen. Serial imaging showed that image acquisition 120 h after injection delivered the best tumor-to-blood pool ratio. Most tumor lesions were visualized with the tracer dose only versus the coinjection imaging acquisition (25% vs. 13.5% of all lesions). Uptake heterogeneity was observed within (SUVpeak range, 0.2-15.1) and between patients. Tumor uptake was higher in patients with treatment response or stable disease than in patients with disease progression according to RECIST 1.1. However, this difference was not statistically significant (median SUVpeak , 4.9 vs. 2.4; P = 0.06). SUVpeak correlated better with the combined tumor and immune cell PD-L1 score than with PD-L1 expression on tumor cells, although neither was statistically significant ( P = 0.06 and P = 0.93, respectively). Conclusion:89 Zr-durvalumab was safe, without any tracer-related adverse events, and more tumor lesions were visualized using the tracer dose-only imaging acquisition.89 Zr-durvalumab tumor uptake was higher in patients with a response to durvalumab treatment but did not correlate with tumor PD-L1 immunohistochemistry., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
30. Study of 89 Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer.
- Author
-
Niemeijer AN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van der Veen BJ, Bahce I, Vugts DJ, van Dongen GAMS, Thunnissen E, Smit EF, and de Langen AJ
- Subjects
- Antibodies, Monoclonal, Humanized, B7-H1 Antigen metabolism, Humans, Positron Emission Tomography Computed Tomography, Programmed Cell Death 1 Receptor, Tissue Distribution, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms diagnostic imaging, Lung Neoplasms drug therapy, Lung Neoplasms metabolism
- Abstract
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for selecting non-small cell lung cancer (NSCLC) patients for single-agent treatment with pembrolizumab, a programmed cell death 1 (PD-1) monoclonal antibody. However, not all patients respond to therapy. Better understanding of in vivo drug behavior may help in the selection of patients who will benefit the most. Methods: NSCLC patients eligible for pembrolizumab monotherapy as first- or later-line therapy were enrolled. Patients received 2 injections of
89 Zr-pembrolizumab, 1 without a preceding dose of pembrolizumab and 1 with a preceding dose of 200 mg of pembrolizumab, directly before tracer injection. Up to 4 PET/CT scans were obtained after tracer injection. After imaging acquisition, patients were treated with 200 mg of pembrolizumab every 3 wk. Tumor uptake and tracer biodistribution were visually assessed and quantified as the SUV. Tumor tracer uptake was correlated with PD-1 and PD-L1 expression and response to pembrolizumab treatment. Results: Twelve NSCLC patients were included. One patient experienced grade 3 myalgia after tracer injection.89 Zr-pembrolizumab was observed in the blood pool, liver, and spleen. Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring ΒΧΡ20 mm in the long-axis diameter, and substantial uptake heterogeneity was observed within and between patients. Uptake was higher in patients with a response to pembrolizumab treatment ( n = 3) than in patients without a response ( n = 9), although this finding was not statistically significant (median SUVpeak , 11.4 vs. 5.7; P = 0.066). No significant correlations were found with PD-L1 or PD-1 immunohistochemistry. Conclusion:89 Zr-pembrolizumab injection was safe, with only 1 grade 3 adverse event-possibly immune-related-in 12 patients.89 Zr-pembrolizumab tumor uptake was higher in patients with a response to pembrolizumab treatment but did not correlate with PD-L1 or PD-1 immunohistochemistry., (© 2022 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2022
- Full Text
- View/download PDF
31. Quantification of PD-L1 Expression with 18 F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
- Author
-
Huisman MC, Niemeijer AN, Windhorst AD, Schuit RC, Leung D, Hayes W, Poot A, Bahce I, Radonic T, Oprea-Lager DE, Hoekstra OS, Thunnissen E, Hendrikse NH, Smit EF, de Langen AJ, and Boellaard R
- Subjects
- Carcinoma, Non-Small-Cell Lung pathology, Humans, Lung Neoplasms pathology, Models, Biological, B7-H1 Antigen analysis, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Fluorine Radioisotopes pharmacokinetics, Lung Neoplasms diagnostic imaging, Positron Emission Tomography Computed Tomography methods, Radiopharmaceuticals pharmacokinetics
- Abstract
The aim of this work was to quantify the uptake of
18 F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non-small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with18 F-BMS-986192 in patients with advanced-stage non-small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of18 F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time-activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time-activity curves. The distribution volume ( VT ) ranged from 0.4 to 4.8 mL⋅cm-3 Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT , with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer18 F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended., (© 2020 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.